Compass Therapeutics has struck a deal to acquire a clinical-phase bispecific antibody. The deal will see Compass buy Trigr Therapeutics for a DLL4xVEGF-A candidate that is being studied in patients with solid tumors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,